CM512 clinical trials
How each study uses CM512 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the CM512 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
10 studies that test it; most in 2025 (6)
| Year | Studies |
|---|---|
| 2024 | 1 |
| 2025 | 6 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 0
Keymed Biosciences Co.Ltd (7) · Beijing Keymed Biosciences Co., Ltd. (3)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 1 in phase 3
Studies that test CM512, phase 3 first.
- Nov 2027A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis (NEZHA-3)Phase 3 · Beijing Keymed Biosciences Co., Ltd.
- Nov 2026Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU)Phase 2 · Keymed Biosciences Co.Ltd
- Jul 2027Study of CM512 Injection in Subjects With Moderate-to-severe AsthmaPhase 2 · Keymed Biosciences Co.Ltd
Studies
Open first, then newest update. How each study uses CM512 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- Study of CM512 Injection in Patients With Perennial Allergic Rhinitis on Background TherapyNot yet recruitingPhase 2Beijing Keymed Biosciences Co., Ltd.NCT07890350Written as CM512
- A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis (NEZHA-3)Not yet recruitingPhase 3Beijing Keymed Biosciences Co., Ltd.NCT07807826Written as CM512
- A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis (NEZHA-2)Not yet recruitingPhase 2Keymed Biosciences Co.LtdNCT07519577Written as CM512
- Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU)RecruitingPhase 2Keymed Biosciences Co.LtdNCT07166211Written as CM512 injection
- A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis.RecruitingPhase 2Keymed Biosciences Co.LtdNCT07230483Written as CM512
- Study of CM512 Injection in Subjects With Moderate-to-severe AsthmaRecruitingPhase 2Keymed Biosciences Co.LtdNCT07011524Written as CM512 injection
- Study of CM512 in Patients With Moderate-to-Severe Atopic DermatitisRecruitingPhase 2Keymed Biosciences Co.LtdNCT06947980Written as CM512
- A Study of CM512 in Subjects With Moderate-to-Severe Chronic Obstructive Pulmonary DiseaseNot yet recruitingPhase 2Keymed Biosciences Co.LtdNCT06980142Written as CM512
- A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis (NEZHA-1)CompletedPhase 2Beijing Keymed Biosciences Co., Ltd.NCT06930612Written as CM512
- Study of CM512 in Healthy Subjects and Patients With Atopic DermatitisCompletedPhase 1Keymed Biosciences Co.LtdNCT06553209Written as CM512
What changed recently
From the registry's own updates since Oct 17, 2026.
Newly registered1
- Study of CM512 Injection in Patients With Perennial Allergic Rhinitis on Background TherapyOct 22, 2026NCT07890350